



photonamic

photonamic GmbH & Co. KG successfully obtains Manufacturing License under GMP

Pinneberg, Germany – April 3rd, 2024:

After successful completion of planned inspections by the local health authorities, photonamic GmbH & Co. KG (photonamic), a pharmaceutical company focused on the development of 5-aminolevulinic acid (5-ALA) in various applications, was granted a Manufacturing License under GMP on March 27, 2024. With this new status, the company is now qualified to manufacture and release its pharmaceutical products for distribution. photonamic collaborates closely with contract manufacturers, but has also worked strategically on the incorporation of key supply functions into the organization.

“The granting of this license marks a new level in our position as a fully-integrated pharmaceutical company. Having the necessary licenses as well as the expertise in-house provides us with increased flexibility, independence, and reliability for the supply chain of our 5-ALA specialty products. I am very proud of what our team has achieved,” states CEO Ulrich Kosciessa, photonamic.

photonamic has recently on-boarded several new colleagues with extensive experience in manufacturing and quality control under Good Manufacturing Practice, and thus built up the necessary competencies and resources to ensure consistent high-quality and timely product supply. The company has several ongoing clinical trials with 5-ALA, and ambitions to expand the trial portfolio even further. The newly obtained license will enable the supply for these clinical trials as well as meet the increasing demand for commercial use of photonamic’s already approved ALA products, particularly in the area of fluorescence-guided surgery.

About photonamic GmbH & Co KG

photonamic is a German based company focused on the development and manufacturing of 5-ALA in various applications in the health care field. As a member of the SBI group with its parent company SBI ALApharma Hong Kong, the main achievement of photonamic to date is the development and registration of 5-ALA for the fluorescence-guided resection of glioblastoma which is marketed as Gliolan[®], Gleolan[™] or Alabel[™] in Europe, United States, Canada, Japan, Australia and Korea. Within the group, photonamic and its affiliated companies in the US, Canada and Japan are diligently extending the development activities with 5-ALA even outside the field of photodynamic application, e.g. immune modulation in infectious diseases, food supplement and cosmetics.